1. A conjugate ligand-drug according to the formula: or a pharmaceutically acceptable salt thereof, having the specificity against the target cells expressing DR5, where: L - link ligand which is an antibody against DR5, comprising (a) an immunoglobulin heavy chain, y wherein CDR1 comprises amino acid residues 1-5 SEQ ID NO: 11, CDR2 comprises amino acid residues 1-17 SEQ ID NO: 12, a CDR3 consisting of amino acid residues 1-13 SEQ ID NO: 13 and (b) an immunoglobulin light chain, in which CDR1 comprises amino acid residues 1-16 SEQ ID NO: 14, CDR2 comprises amino acid residues 1-7 SEQ ID NO: 15, a CDR3 consisting of amino acid residues 1-9 SEQ ID NO : 16 and (LU-D) - linker moiety Link-link the medicament, where: LU - linker unit, AD - link medicament, wherein the medicament is presented link auristatin ipodstrochny index p - an integer from 1 to 20.2. The conjugate of ligand-drug according to Claim. 1, wherein the auristatin is represented auristatin E, AEB, AEVB, AFP, MMAF or MMAE.3. The conjugate-ligand medicament according to claim 1 having the formula: or a pharmaceutically acceptable salt thereof, wherein:. S - sulfur atom at the ligand level, and each W is independently an amino acid unit subscript w - an integer from 0 to 12 -Y- It means a spacer unit apodstrochny index y is equal to 0.1 or 2.4. The conjugate-ligand medicament according to claim. 3, wherein Woznachaet tsitrullin.5-valine. The conjugate-ligand medicament according to claim 1 having the formula: ililibo a pharmaceutically acceptable salt thereof, wherein:. MAb - antibody against DR5 S - sulfur atom in the antibody apodstrochny index p - an integer from 1 to 8.6. The conjugate-ligand medicament according to claim 1, wherein the anti-DR5 antibody comprises a heavy chain variable region comprising amino acid residues 1-122 SEQ ID NO:. 9, and the variable region of the light chain,1. Конъюгат лиганд-лекарственное средство, соответствующий формуле:или его фармацевтически приемлемая соль, обладающая
